Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q1 Loss of 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $163.77 -0.66%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.84 million.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen on Neurocrine Bio. (NBIX): 'This latest Crenessity beat may serve as the positive inflection point'
- Intel shares fall as competitor reports record results
- Netflix gains after Ackman endorsement and AI feature launch
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
